MASTER trial updates: Dara-KRd induction, autologous transplantation and MRD response-adapted consolidation in NDMM

UKALL2011: Treatment with a tyrosine kinase inhibitor improves outcomes for patients with acute lymphoblastic leukaemia and an ABL-class fusion

Phase I/II results: First-line NALIRIFOX in patients with pancreatic ductal adenocarcinoma

Long-term disease control in multiple myeloma by in-class transitioning: A community-based study

Venetoclax plus navitoclax in R/R ALL and lymphoblastic lymphoma

Treating acute lymphoblastic leukaemia in the era of COVID-19

COVID-19 and impact on gynecologic oncology practice in India: Results of a nationwide survey

The future of PARP inhibitors in prostate cancer

Managing acute myeloid leukaemia during the COVID-19 pandemic

Meet the Expert: Daniel Seymour

Gut microbiome disturbance by antibiotic treatment early in life is sufficient to induce leukaemia in predisposed mice

COMBI-AD trial: Adjuvant dabrafenib plus trametinib in patients with resected stage III BRAF V600–mutant melanoma